CoChat

Prevalence of visual field loss following exposure to vigabatrin therapy: A systematic review

Maguire, Melissa J., Hemming, Karla, Wild, John M., Hutton, Jane L., Marson, Anthony G. · 2010 · Epilepsia
Cited by 159

The DOI matches its Crossref record.

Abstract

Summary: Purpose: Vigabatrin is an efficacious antiepileptic drug licensed as add‐on therapy in refractory epilepsy and used in infantile spasms. Eight years after licensing, there emerged a strong and possibly causative association with bilateral visual field loss. We report a systematic review ascertaining the magnitude of risk of vigabatrin associated visual field loss (VAVFL) and any clinical predictors of risk. Methods: Electronic searches, including MEDLINE (1966–2009), EMBASE (1974–2009), and CINAHL (1982–2009), were conducted. Reports, published in full, of observational studies investigating the prevalence of visual field loss in patients with partial epilepsy treated with vigabatrin were included. Outcomes were the proportion with visual field loss, and the relative risk of VAVFL compared to similar nonexposed patients with epilepsy. Key Findings: Thirty‐two studies were identified, which included 1,678 patients exposed to vigabatrin and 406 controls. Of the 1,678 exposed patients, 738 (44%) had visual field loss compared to just 30 (7%) among the 406 controls. The random‐effects estimate for the proportion of adults with visual field loss was 52% [95% confidence interval (CI) 46–59]. The estimate for children was lower at 34% (95% CI 25–42). The relative risk for field loss in vigabatrin‐exposed patients was 4.0 (95% CI 2.9–5.5). Larger mean cumulative dose of vigabatrin and increasing age were associated with a higher proportion of patients with visual field loss. Significance: Vigabatrin should be reserved for patients with epilepsy for whom there is no other alternative or for patients who have determined the benefit of ongoing treatment to outweigh the risk of VAVFL.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1528-1167.2010.02772.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 159

Metadata

Authors
Maguire, M. J., Hemming, K., Wild, J. M., Hutton, J. L., & Marson, A. G.
Venue
Epilepsia
Publisher
Wiley
Published
2010-11-10
Volume
51
Issue
12
Pages
2423-2431
ISSN
  • 0013-9580 (ISSN-L)
  • 1528-1167
OpenAlex
W1948601338
Cited by
159
References
0
FWCI
3.49
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prevalence of visual field loss following exposure to vigabatrin therapy: A systematic review. https://app.cochat.ai/papers/10.1111/j.1528-1167.2010.02772.x
The paper
Maguire, M. J., Hemming, K., Wild, J. M., Hutton, J. L., & Marson, A. G. (2010). Prevalence of visual field loss following exposure to vigabatrin therapy: A systematic review. Epilepsia. https://doi.org/10.1111/j.1528-1167.2010.02772.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.